Dr. Taylor on Treatments in Development for Endometrial Cancer

Alexandra Taylor, MD
Published: Thursday, Jan 04, 2018



Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses treatments in development for patients with endometrial cancer.

There is a better knowledge of the molecular changes that can guide physicians toward specific pathways where targeted agents may have activity, explain Taylor.

According to Taylor, there are many phase II studies investigating single-agent targeted therapies, particularly with the mTOR inhibitors targeting the PI3-kinase pathway, as well as the antiangiogenic agents.
 


Alexandra Taylor, MD, consultant, clinical oncology, The Royal Marsden Hospital, discusses treatments in development for patients with endometrial cancer.

There is a better knowledge of the molecular changes that can guide physicians toward specific pathways where targeted agents may have activity, explain Taylor.

According to Taylor, there are many phase II studies investigating single-agent targeted therapies, particularly with the mTOR inhibitors targeting the PI3-kinase pathway, as well as the antiangiogenic agents.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x